Therapeutic regimens for such cancers include selective estrogen receptor modulators or aromatase inhibitors (AIs); however, a significant percentage of ER-positive cancers become resistant upon repeat dosing of selective estrogen receptor modulator- or AI-based therapies (9). This evidence concerns the gene CYP19A1 and cancer.